Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Oncol. 2010;2010:961243. doi: 10.1155/2010/961243. Epub 2010 Jun 20.

Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Author information

  • 1Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.

Abstract

Progression of malignant brain tumors is dependent upon vascularity and is associated with altered ganglioside composition and distribution. Evidence is reviewed showing that the simple monosialoganglioside, GM3, possesses powerful antiangiogenic action against the highly vascularized CT-2A mouse astrocytoma, which primarily expresses complex gangliosides. Brain tumors expressing high levels of GM3 are generally less vascularized and grow slower than tumors that express low levels of GM3. GM3 inhibits angiogenesis through autocrine and paracrine effects on vascular endothelial growth factor (VEGF) and associated receptors. GM3 should be a clinically useful compound for managing brain tumor angiogenesis.

PMID:
20634908
[PubMed]
PMCID:
PMC2904445
Free PMC Article

Images from this publication.See all images (8)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk